HCPCS Level II code C9739 denotes cystourethroscopy with insertion of transprostatic implant(s) — specifically placement of one to three implants during an endoscopic urologic procedure. The code captures a minimally invasive approach to address prostatic obstruction or related lower urinary tract conditions by delivering intraprostatic implants under cystoscopic guidance. Nationally, this code is relevant as device-based, office-to-ambulatory-site procedures expand and payers refine coverage and reimbursement policies for urologic implants.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of the clinical service represented by the code, common sites of service, and typical billing context. The publication also summarizes benchmark considerations and policy themes payers address for implantable urologic therapies, outlines coding and documentation implications, and highlights areas where payers commonly require additional clinical evidence or prior authorization.

This summary is designed to give clinicians, billing staff, and policy analysts a clear, actionable understanding of what C9739 represents, why it matters in the evolving landscape of urologic device-based care, and what topics to review when preparing claims or evaluating coverage.